September 09, 2024

Discontinuation of CML Therapy: Which Patients Are Ideal Candidates?

“Stopping tyrosine kinase inhibitor therapy is something we get a lot of questions about from both patients and their referring physicians,” said Amelia A. Langston, MD. Although their efficacy is ind...

The ASCO Post

September 09, 2024

Addition of Pembrolizumab to Chemotherapy in EGFR TKI-Resistant, EGFR-Mutant, Metastatic Nonsquamous NSCLC

As reported in the Journal of Clinical Oncology by Yang et al, the phase III KEYNOTE-789 trial evaluated the survival impact of adding pembrolizumab to pemetrexed/platinum in EGFR tyrosine kinase inhi...

The ASCO Post

September 09, 2024

Too Much, Too Little, Just Right: Optimizing Cancer Care for Older Adults

Addressing the disparities in cancer treatment for older adults, this article discusses the challenges of optimizing treatment, proposing tailored interventions to ensure personalized and appropriate care. Authors highlight the need for changes in trial practices and treatment approaches.

The ASCO Post

September 06, 2024

Cancer Diagnoses Lag Post-Pandemic, Study Reveals

Despite recovery efforts, U.S. cancer diagnoses remained 2.7% below expected levels in 2021, potentially leaving about 150,000 cases undetected over 2 years of COVID-19 pandemic–related disruptions.

Conexiant

September 06, 2024

FDA Approves Ready-to-Use Version of Bortezomib for Subcutaneous Administration

The FDA has approved a new presentation of bortezomib (Boruzu) for ready-to-use subcutaneous or intravenous administration. This proteasome inhibitor is used for the treatment of multiple myeloma and ...

The ASCO Post

September 06, 2024

WTC Study Reveals Epigenetic Cancer Risk Markers

World Trade Center exposure is linked to substantial DNA methylation changes, with 14.3% hypermethylated sites in exposed cancer-free individuals versus 4.5% in unexposed controls.

Conexiant

September 05, 2024

Minimizing the Risk of Cancer Therapy–Induced Oral Mucositis

A study investigated the use of topical agents to prevent oral mucositis in cancer therapy patients, revealing sucralfate as the most effective treatment option.

Conexiant

September 05, 2024

Colonoscopy AI System Receives FDA Clearance

FDA clears first cloud-based AI colonoscopy assistant, potentially improving adenoma detection rates without increasing procedure time or risks.

Conexiant

September 05, 2024

J&J Adds $1.1B to Resolve Talc Cancer Claims

The company plans to use a "Texas two-step" bankruptcy strategy to consolidate all talc claims.

Reuters